This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: Oct. 25

1. Repros Rebuke

The brains behind Repros Therapeutics (RPRX) are clearly not beyond reproach.

Shares of Repros tumbled nearly 30% to around $17 Wednesday after the company admitted that the FDA has raised concerns about the reliability of some of the clinical data collected during the phase III studies of its testosterone boosting drug Androxal. These are the Androxal studies, in case you may have forgotten, in which Repros admitted that one enrolling site fabricated clinical data, while another collected anomalous data due to Gay Cuban men having too much sex.

Yeah, we know. It's hard to forget our friends at good old Repros, but unlike CEO Joe Podolski, we like to cover all our bases.

And as TheStreet's biotech ax Adam Feuerstein alertly points out, it's also the same good old Repros which just last month assured investors that the FDA would find nothing wrong with the clinical data supporting Androxal. In the same release, Podolski added, "We are confident in the reliability of our results and the positive outcome of our two clinical trials."

Podolski's September promise about the high quality of the Androxal data helped Repros shares climb to four-year high. Repros, which by the way has no revenue, is now trading where it did in June, before the big biotech summer rally began.

Nevertheless, just because the stock gave up its gains doesn't mean it's cheerleaders on Wall Street are giving up the ghost.

Lazard analyst Josh Schimmer told clients in a note that "the slight delay to tighten Androxal filing is worthwhile." Meanwhile, Brean Capital analyst Jon Aschoff blew off the FDA's concerns and said the latest Androxal data twist "could be positive in the end."

Of course, they very well could be proven right in the long run.

Until Repros offers more proof to back up its claims, however, all we can offer back to Repros is a reproof.

-- Written by Gregg Greenberg in New York

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
FB $82.26 2.30%
GOOG $538.26 -0.17%
TSLA $248.94 0.24%
YHOO $43.43 0.65%
AAPL $130.29 0.25%

Markets

DOW 18,088.18 +76.24 0.42%
S&P 500 2,118.68 +9.08 0.43%
NASDAQ 5,108.8390 +32.3150 0.64%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs